Clinical trial · Observational
Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care
Retrospective Observational Study Determining the Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to determine the clinical effectiveness of whole-genome and transcriptome analysis (WGTA) to guide advanced cancer care. The study setting is the British Columbia (BC) Personalized OncoGenomics (POG) program, a single group research study of WGTA guiding treatment planning for patients with advanced, incurable cancers (NCT02155621). To characterize clinical effectiveness, the survival impacts of POG's approach compared to usual care in matched controls will be estimated.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Cancers That Cannot be Treated With Curative Intent | — | UNRESOLVED | — |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Initiation of POG-related WGTA | Genetic | — | UNRESOLVED |
| Usual care | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- POG patients
- description
- Patients enrolled in POG who initiated WGTA between July 2014 and December 2017
- interventionNames
- Genetic: Initiation of POG-related WGTA
- label
- Usual care controls
- description
- Matched controls who received usual care and were diagnosed with metastatic cancer prior to December 2017
- interventionNames
- Genetic: Usual care
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- From 1 year up to 4.5 years, adjusted for censoring
- description
- Identified from BC Cancer Registry data
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria (POG Patients): * BC residency * Metastatic disease considered incurable by their treating oncologist * Life expectancy \> 6 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Consented to POG and undergone initial biopsy between July 2014 and December 2017 Inclusion Criteria (Usual Care Patients): * Diagnosed with cancer prior to December 2017 * BC residents during study period * Received care at BC Cancer during study period * Alive July 1st 2014 Exclusion Criteria (All Patients): * BC Medical Services Plan personal health number missing or invalid * Cancer case diagnosed at death * Age at diagnosis ≤18
References
Publications (2)
- BACKGROUNDLaskin J, Jones S, Aparicio S, Chia S, Ch'ng C, Deyell R, Eirew P, Fok A, Gelmon K, Ho C, Huntsman D, Jones M, Kasaian K, Karsan A, Leelakumari S, Li Y, Lim H, Ma Y, Mar C, Martin M, Moore R, Mungall A, Mungall K, Pleasance E, Rassekh SR, Renouf D, Shen Y, Schein J, Schrader K, Sun S, Tinker A, Zhao E, Yip S, Marra MA. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000570. doi: 10.1101/mcs.a000570. PMID 27148575
- BACKGROUNDDiamond A, Sekhon JS. Genetic matching for estimating causal effects: A general multivariate matching method for achieving balance in observational studies. Review of Economics and Statistics. 95(3):932-945, 2013.